Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Study Number

4766925

Phase

Age Group

Adult

Principal Investigator

Purpose

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Check your eligibility for this trial

Check now

Full Title

A Phase 1 First-in-Human Study of PTK7-Directed Antibody-Drug Conjugate HWK-007 in Participants with Advanced Solid Tumors

ClinicalTrials.Gov ID

NCT07444814

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.